AB 2095: Medi-Cal: prescriptions.
- Session Year: 2015-2016
- House: Assembly
- Latest Version Date: 2016-03-18
Existing law establishes the Medi-Cal program, administered by the State Department of Health Care Services, under which health care services are provided to qualified, low-income persons. The Medi-Cal program is, in part, governed and funded by federal Medicaid Program provisions.
This bill would require the Legislative Analysts Office to conduct or cause to be conducted a study comparing the purchase or administration of brand name prescription medications through the Medi-Cal program to the purchase or administration of biosimilars through the Medi-Cal program, as specified. The bill would require the study to cover the 201314 and 201415 fiscal years and to be completed on or before January 1, 2018.
Existing law creates various state agencies and authorizes certain of those agencies to regulate the operations of businesses. Existing law, until January 1, 2018, authorizes cities and counties to establish capital investment incentive programs to attract large manufacturing facilities to invest in their communities and to encourage industries, such as high technology, aerospace, automotive, biotechnology, software, and environmental sources and others, to locate and invest in those facilities in California.
This bill would express the intent of the Legislature to enact legislation that would enhance and advance opportunities for Californias biotechnology industry.
Existing law creates various state agencies and authorizes certain of those agencies to regulate the operations of businesses. Existing law, until January 1, 2018, authorizes cities and counties to establish capital investment incentive programs to attract large manufacturing facilities to invest in their communities and to encourage industries, such as high technology, aerospace, automotive, biotechnology, software, and environmental sources and others, to locate and invest in those facilities in California.
This bill would express the intent of the Legislature to enact legislation that would enhance and advance opportunities for Californias biotechnology industry.
The Legislative Analysts Office shall conduct or cause to be conducted a study comparing the purchase or administration of brand name prescription medications through the Medi-Cal program to the purchase or administration of biosimilars through the Medi-Cal program. The study shall cover the 201314 and 201415 fiscal years and shall be completed on or before January 1, 2018. The study shall breakdown the information by the age, ethnicity, and gender of the Medi-Cal recipients who purchase those medications or to whom the medications are administered.
SECTION 1.It is the intent of the Legislature to enact legislation that would enhance and expand opportunities for Californias biotechnology industry.
It is the intent of the Legislature to enact legislation that would enhance and expand opportunities for Californias biotechnology industry.
|
Date
|
Status
|
|---|---|
| Feb 17, 2016 | Read first time. To print. |
| Feb 18, 2016 | From printer. May be heard in committee March 19. |
| Mar 17, 2016 | Referred to Com. on HEALTH. |
| Mar 18, 2016 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Mar 28, 2016 | Re-referred to Com. on HEALTH. |
| Apr 12, 2016 | In committee: Set, first hearing. Hearing canceled at the request of author. |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
Bill Author
Bill Co-Author(s):